Visit us at Booth #321 at PEGS Europe in Lisbon, Portugal.
Accelerating the Discovery of Therapeutic Antibodies Using High Throughput SPR
Presenter: Judicaël Parisot PhD, Senior Field Applications Scientist, Carterra
Throughput, speed, resolution, and sample consumption are typically key limiting- factors for detailed kinetic characterization early in antibody discovery campaigns. Here, we show that high throughput surface plasmon resonance (SPR) can be used to rapidly generate high quality kinetic data from 384 antibodies in parallel with minimal sample consumption. Additionally, epitope binning assays can be performed routinely on up to 384 antibodies per array, providing unprecedented throughput that allows for early assessment of your library’s epitope coverage with exquisite epitope discrimination, facilitating the identification of clones targeting unique epitopes. The ability to characterize binding kinetics, affinity, and epitope specificity on large antibody panels with minimal sample consumption at early stage research is highly advantageous in drug discovery because it helps to accelerate library-to-lead triage.
Next Generation Phage Antibody Libraries for Drug Discovery: Enhanced Affinity and Developability Straight from Selections
Presenter: André Teixeira, PhD, Scientist, Specifica Inc.
Date: Tuesday, 19 November
Time: 12:45 – 13:15
To make good antibodies and antibody drug conjugates (ADC) it is important to start with antibodies with ideal developability profiles. Beyond high affinity and specificity to the intended target, resistance to aggregation when in solution, thermal stability to prevent unfolding, and minimal polyreactivity are essential desired properties. Overlooking these aspects during early development can lead to poor outcomes in later development stages. Generating developable leads that score well in all these parameters may need extensive clone screening or downstream engineering that can be very challenging and time-consuming. In this work, we present a new antibody display library architecture designed to yield high affinity (pM or low nM range measured using SPR/Carterra), and highly developable antibodies straight from the initial selection campaign. The combination of natural diversity with clinically proven scaffolds enables the rapid discovery of good leads for ADC and antibody therapy.